產(chǎn)品名稱：Ruxolitinib, Free Base 產(chǎn)品貨號：LC R-6600 產(chǎn)品規(guī)格：100 MG This is the free base form of ruxolitinib, also known as INCB18424; please see the other form of this product, Ruxolitinib, Phosphate Salt, Cat. No. R-6688, for further technical information. The phosphate salt form of ruxolitinib is used for some or all ruxolitinib formulations for use in humans. Ruxolitinib (as the phosphate salt) is the active ingredient in the drug sold under the trade name Jakafi® by Incyte Corporation. Jakafi® is currently approved in at least one country for use in patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. NOTE: THE RUXOLITINIB, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT JAKAFI® AND IS NOT FOR HUMAN USE. Jakafi® is a registered trademark of Incyte Corporation. LC Laboratories is not affiliated with Incyte Corporation, and the ruxolitinib research compounds sold by LC Laboratories are not manufactured by Incyte Corporation. This ruxolitinib product research compound is the free base, whose CAS number is given above. The CAS number of the phosphate salt is 1092939-17-7. As of September 2011, it appears that Chemical Abstracts Service currently also has a second CAS number for Ruxolitinib, Free Base, namely 1160597-27-2. Another CAS number previously assigned to Ruxolitinib, Free Base, namely 1138325-12-8, has been deleted by CAS and is no longer in use. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 28 mg/mL; soluble in ethanol at 15 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 25-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A
滬公網(wǎng)安備 31011002002623號
